OmniSeq receives New York State CLEP approval

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

OmniSeq, a subsidiary of Roswell Park Cancer Institute, received New York State Clinical Laboratory Evaluation Program approval for its OmniSeq Comprehensive panel, a 144 gene, pan-cancer, next-generation sequencing tumor profiling diagnostic panel to guide oncology treatment decision-making.

“OmniSeq is proud to receive New York State CLEP approval for OmniSeq Comprehensive. CLEP is the highest standard of Clinical Laboratory Improvement Amendments laboratory validation,” said Carl Morrison, president and chief scientific officer of OmniSeq and executive director of the Roswell Park Center for Personalized Medicine.

YOU MAY BE INTERESTED IN

In April 2025, announcements from the two most influential biomedical agencies in the US, the FDA and the NIH, declared that both will seek to reduce and minimize animal-based testing and experimentation. These declarations sparked joy in some circles, and deep concern in others that was reflected in a 28% fall in the share price of Charles River Labs (NYSE: NYSE:CRL). 
Over the past three decades, cancer genetics has transformed precision oncology. Germline testing has advanced from single-gene Sanger sequencing to parallel sequencing of hundreds of genes, while tumor (somatic) testing has expanded with the rise of targeted therapies based on point mutations, copy number changes and other alterations. 

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login